Development of antibody surrogates for the treatment of cancers and autoimmune disease
- 31 December 2010
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Chemical Biology
- Vol. 14 (6), 721-727
- https://doi.org/10.1016/j.cbpa.2010.07.002
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Seamless Bead to Microarray Screening: Rapid Identification of the Highest Affinity Protein Ligands from Large Combinatorial LibrariesCell Chemical Biology, 2010
- Isolation of Antagonists of Antigen-Specific Autoimmune T Cell ProliferationCell Chemical Biology, 2009
- Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate CancerJournal of the American Chemical Society, 2009
- Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory PainCell Chemical Biology, 2009
- Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probesNature Biotechnology, 2009
- A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 ActivityJournal of the American Chemical Society, 2008
- The B Cell SlayerScience, 2007
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imagingNature Chemical Biology, 2006
- Natural DNP-binding immunoglobulins and antibody multispecificityMolecular Immunology, 1984